**Name of journal:** World Journal of Clinical Cases  

**Manuscript NO:** 71680  

**Title:** Elemene-containing hyperthermic intraperitoneal chemotherapy combined with oxaliplatin and capecitabine chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer: A prospective analysis  

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed  

**Peer-review model:** Single blind  

**Reviewer’s code:** 05194798  

**Position:** Editorial Board  

**Academic degree:** MD  

**Professional title:** Director  

**Reviewer’s Country/Territory:** Japan  

**Author’s Country/Territory:** China  

**Manuscript submission date:** 2021-09-18  

**Reviewer chosen by:** AI Technique  

**Reviewer accepted review:** 2021-10-04 00:57  

**Reviewer performed review:** 2021-10-08 11:32  

**Review time:** 4 Days and 10 Hours  

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

This manuscript is an original article that investigated the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) containing elemene, combined with reduced CapeOx chemotherapy regimens in elderly patients with peritoneal metastatic gastric cancer. The authors showed HIPEC containing elemene with reduced CapeOx chemotherapy attenuated the side effects, such as myelosuppression with the comparable outcomes, compared with the lobarplatin-based regimen. The results will be of interest to clinicians in the field. However, the following major and minor issues require clarification: Major 1. I think this study is prospective but not retrospective as a total of 39 patients were randomly divided into two groups. Therefore, the authors should provide a flow chart of the study process including excluded patients. 2. The authors concluded that the elemene-containing HIPEC combined with CapeOx reduction regimen can extend the overall survival. However, its predominance regarding the OS was not statistically proven in this study. Please reconsider the conclusion. 3. The composition of the contents seems unsophisticated. A kind of methods was described in the Results section, a sentence including discussion was found in the Results section, some contents which should be written in the introduction section were described in the Discussion section, and most description in the conclusion should be written in the Discussion section. Please reconsider them. Minor 1. (Title) Please spell out “HIPEC” and “CapeOx”. 2. Please explain why the patients with hypertension were excluded. 3. The authors should provide the data of other treatment before and after these regimens. 4. (Table1) Please provide the data of the performance status. 5.
(Table 1) “Abdominal infection” is duplicated. 6. (P13L16-17) Please spell out “FLOT4” and “DCF”. 7. (Figure 1) Please draw the line of Group M clearly.
Name of journal: World Journal of Clinical Cases

Manuscript NO: 71680

Title: Elemene-containing hyperthermic intraperitoneal chemotherapy combined with oxaliplatin and capecitabine chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer: A prospective analysis

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03806663

Position: Editorial Board

Academic degree: MD

Professional title: Professor

Reviewer’s Country/Territory: Egypt

Author’s Country/Territory: China

Manuscript submission date: 2021-09-18

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-10-10 09:34

Reviewer performed review: 2021-10-12 12:31

Review time: 2 Days and 2 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ ] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[Y] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>
Re-review | [Y] Yes  [ ] No
---|---
Peer-reviewer statements | Peer-Review: [Y] Anonymous  [ ] Onymous
| Conflicts-of-Interest: [ ] Yes  [Y] No

**SPECIFIC COMMENTS TO AUTHORS**

this work is interesting, as it discusses a hot issue, but i have some comments: 1- the sample size is small 2- this is a single center study, you need more randomized multicenter studies to prove the role of Elemene 3- are the pharmacokinetics and pharmacodynamics of elemene well studied?